{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006912","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.753174+00:00","generated_at":"2026-05-15T21:56:08.670692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImmuCell reports 2025 net operating income $1.6M; net loss narrows to $1.0M","bullets":["Product sales $27.6M, up 4.3% YoY; gross margin improved to 41.4% from 30%.","Net loss $1.0M ($0.12/share) vs $2.2M ($0.26/share) in 2024.","Net operating income $1.6M vs operating loss $1.6M in 2024.","Non-recurring items: $2.7M Re-Tain write-down, $651K colostrum write-downs, $297K CEO transition costs, $427K insurance proceeds.","Cash $3.8M, no debt draw; net working capital $13M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006912","json":"https://secwatch.observer/filing/0001437749-26-006912.json","markdown":"https://secwatch.observer/filing/0001437749-26-006912.md","text":"https://secwatch.observer/filing/0001437749-26-006912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926006912/0001437749-26-006912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926006912/iccc20260304_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:56:08.670692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}